Covid-19 costs Coloplast USD 33m in extended court cases

Medtech company Coloplast has set aside a further USD 33m to pay for compensation in the remaning cases over its vaginal mesh product in the US. The covid-19 crisis has delayed court cases and increased the cost of legal counsel, but the financial director expects this amount to be enough to but the cases behind them.
Financial director Anders Lonning-Skovgaard | Photo: Niels Hougaard/ERH
Financial director Anders Lonning-Skovgaard | Photo: Niels Hougaard/ERH
BY ULRICH QUISTGAARD, TRANSLATED BY CATHERINE BRETT

In Coloplast's Q2 financial report released on Thursday there was a special column for the expensive cloud that is still hanging over the medtech company in the US.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading